Breast Cancer Clinical Research Unit, CNIO Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, 28029, Madrid, Spain.
Histopathology Unit, CNIO Spanish National Cancer Research Center, Madrid, Spain.
Clin Transl Oncol. 2024 May;26(5):1273-1279. doi: 10.1007/s12094-023-03329-9. Epub 2023 Oct 18.
HER2, TROP2 and PD-L1 are novel targets in triple-negative breast cancer (TNBC). The combined expression status of these targets, and whether they can define prognostic subgroups, is currently undefined.
Immunohistochemistry was used to determine HER2, TROP2 and PD-L1 levels in 459 TNBC cases, that received in the adjuvant/neoadjuvant setting active surveillance, CMF, anthracycline-, anthracycline plus taxane-, or carboplatin-containing regimes.
HER2-low patients with PD-L1 > 1 CPS (double-positive, herein "DP") had a mean PFS of 4768 days (95% CI: 4267-5268) versus 3522 days (95% CI: 3184-3861) for non-DP patients (P = 0.002). Regarding the received adjuvant treatment, DP patients (versus non-DP) receiving anthracyclines plus taxanes exhibited a mean PFS time of 4726 (95% CI: 4022-5430) versus 3302 (95% CI: 2818-3785) days (P = 0.039). Finally, 100% of DP patients that received a carboplatin-based regimen were long-term disease-free.
Early HER2-low, PD-L1-positive TNBC patients have a very good prognosis, particularly if treated with anthracycline/taxane- or carboplatin-containing regimes.
HER2、TROP2 和 PD-L1 是三阴性乳腺癌（TNBC）的新靶点。这些靶点的联合表达状态，以及它们是否可以定义预后亚组，目前尚不清楚。
免疫组织化学法检测 459 例 TNBC 患者在辅助/新辅助治疗中接受活性监测、CMF、蒽环类药物、蒽环类药物加紫杉类药物或卡铂治疗方案时的 HER2、TROP2 和 PD-L1 水平。
HER2 低水平且 PD-L1＞1 CPS（双阳性，以下简称“DP”）的患者无进展生存期（PFS）为 4768 天（95%可信区间：4267-5268），而非 DP 患者为 3522 天（95%可信区间：3184-3861）（P=0.002）。关于接受的辅助治疗，接受蒽环类药物加紫杉类药物治疗的 DP 患者（与非 DP 患者相比）的中位 PFS 时间为 4726 天（95%可信区间：4022-5430），而非 DP 患者为 3302 天（95%可信区间：2818-3785）（P=0.039）。最后，100%接受基于卡铂的治疗方案的 DP 患者无疾病长期生存。
早期 HER2 低水平、PD-L1 阳性的 TNBC 患者预后非常好，特别是接受蒽环类药物/紫杉类药物或卡铂治疗方案的患者。
